Actinium Pharmaceuticals
ATNM
Market cap $40.2M

1.29 USD

+0.17

15.18%

At close Dec 20, 4:00 PM EST

After hours

1.25

-0.04

3.10%

1 day

15.18%

5 days

6.61%

1 month

-7.19%

3 months

-28.33%

6 months

-82.91%

Year to date

-75.75%

1 year

-72.26%

5 years

-78.68%

10 years

-99.32%

About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Employees: 49

Healthcare Pharmaceutical Preparations

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

315% more call options, than puts

Call options by funds: $170K | Put options by funds: $41K

15% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 20

2.81% more ownership

Funds ownership: 24.35% [Q2] → 27.16% (+2.81%) [Q3]

0% more funds holding

Funds holding: 72 [Q2] → 72 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 17

70% less capital invested

Capital invested by funds: $53.7M [Q2] → $15.9M (-$37.8M) [Q3]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

210%

upside

Avg. target

$4.50

249%

upside

High target

288%

upside

2 analyst ratings

2 positive

100%

0 neutral

0 negative

Stephens & Co. Sudan Loganathan 26% 1-year accuracy 5 / 19 met price target	288%upside $5	Overweight Reiterated	19 Nov 2024
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 80 / 385 met price target	210%upside $4	Buy Reiterated	15 Nov 2024

See Analyst Rankings

Financial journalist opinion

Positive

Seeking Alpha

1 week ago

My Top 2 Stock Picks For A 2025 Rebound

Tax-loss selling and short-covering dynamics create January Effect Rally opportunities, particularly in small and mid-cap stocks. The AES Corporation is undervalued, offers a 5.4% dividend yield, and is poised to benefit from AI data center energy demand. Actinium Pharmaceuticals, Inc. is a high-risk, high-reward biotech with strong cash reserves, undervalued stock, and a promising cancer treatment pipeline.

Neutral

PRNewsWire

1 month ago

SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha -particle emitting radioisotope, actinium-225, for potential cancer treatments The two sides aim to submit an Investigational New Drug application by 2027, in line with SK Biopharmaceuticals' roadmap to strengthen its radiopharmaceutical therapy business SK Biopharmaceuticals further accelerates the expansion of its radiopharmaceutical therapy pipeline and capability, via strengthened internal resources and partnerships SEOUL, South Korea , Nov. 18, 2024 /PRNewswire/ -- SK Biopharmaceuticals, a biotech company, announced that it has entered into an agreement with the Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea's premier research institution dedicated to the study and advancement of radiological and medical sciences, to collaborate on discovering and developing preclinical radiopharmaceutical drug candidates. This marks the first collaborative research agreement in which both sides will aim to discover radiopharmaceutical compounds and investigate novel oncological treatments, using actinium-225 (225Ac), an alpha-particle emitting radioisotope that selectively kills cancer cells.

Neutral

PRNewsWire

1 month ago

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes - Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 - Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed or refractory acute myeloid leukemia - Accomplished biopharma industry executive June Almenoff, M.D., Ph.D., appointed to Actinium's Board of Directors - Cash and cash equivalents of approximately $78.6 million as of September 30, 2024, is expected to fund operations into 2027 NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted recent regulatory and development updates for its Iomab-B, Actimab-A and Iomab-ACT ARC clinical programs as well as its financial results for the third quarter ended September 30, 2024.

Neutral

Accesswire

1 month ago

Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

$Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm$